Report
Autolus 2Q24 update holds no surprises, obe-cel r/r ALL PDUFA in 4Q24
Autolus reported 2Q24 results in line with expectations, with 2H24 set to be an eventful period for the company. We look forward to FDA decision on obe-cel (CD19 CAR-T) in r/r adult ALL in 4Q24 (PDUFA 16 November) and believe the odds of approval are solid based on the dataset to date. Beyond oncology, initial data from the phase 1 study of obe-cel in SLE will be one to watch, and if positive, could position obe-cel as a pipeline in a product. We reiterate our $11 TP and BUY rating. Autolus remains one of our life sciences top picks, and we see the recent share price dip as a buying opportunity ahead of an eventful 2H24.
Underlying
Autolus Therapeutics ADS
Provider
KBC Securities
We are a financial services provider for several types of professional clients, each with distinct needs.
Jacob Mekhael
Other Reports on these Companies
Other Reports from KBC Securities
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.